China Etanercept Market, 2010-2019 - New Market Report

There are over 300 million people suffering from arthritis around the world. According to the statistics of Centers for Disease Control and Prevention (CDC), about 50 million American suffer from arthritis and this number will rise to 67 million in 2030 on present trends. Besides, direct spending (drugs) and indirect spending (productivity decline) amount to USD 128 billion each year. According to the statistics, there are about 100 million patients with arthritis in China, among which 5-10 million are patients with rheumatoid arthritis (RA). In China, the disability rate of RA is 50% if left untreated in two years and 70% in 3 years.
Developed by Pfizer under the trade name of Enbrel, etanercept is the first completely humanized soluble tumor necrosis factor antagonist for the treatment of RA and ankylosing spondylitis. Its sales value has surpassed USD 8 billion for four successive years. Globally, etanercept is the fifth best-selling drug in 2014 with sales value reaching up to USD 8.54 billion.
After entering China in 2010, etanercept develops fast with annual sales value rising from CNY 2.45 million in 2010 to CNY 23.45 million in 2014 and CAGR during this period reaching up to 75.9%. Currently, etanercept in the Chinese market is monopolized by Boehringer Ingelheim (Germany). According to CRI's market survey, the price range of 25 mg (one injection per package) etanercept in sample hospitals in 2014 was CNY 2032.97-2386.28/package. Although etanercept's market size is not very big due to its relatively high price, it still keeps growing fast. With the economic development and rising incomes, the market for etanercept will be big.

Full Report Details at
- http://www.fastmr.com/prod/1015932_china_etanercept_20102019.aspx?afid=301

Readers can get at least the following information from this report:

* market size of etanercept in China
* price of etanercept in Chinese market
* market outlook of etanercept in China

The author suggests the following groups of people purchase this report:

* manufacturers of arthritis drugs
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Enbrel (etanercept) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2014
- Psoriatic Arthritis - Pipeline Review, H2 2014
- Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2014
- Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth